Literature DB >> 26098200

Sample size considerations for historical control studies with survival outcomes.

Hong Zhu1, Song Zhang1, Chul Ahn1.   

Abstract

Historical control trials (HCTs) are frequently conducted to compare an experimental treatment with a control treatment from a previous study, when they are applicable and favored over a randomized clinical trial (RCT) due to feasibility, ethics and cost concerns. Makuch and Simon developed a sample size formula for historical control (HC) studies with binary outcomes, assuming that the observed response rate in the HC group is the true response rate. This method was extended by Dixon and Simon to specify sample size for HC studies comparing survival outcomes. For HC studies with binary and continuous outcomes, many researchers have shown that the popular Makuch and Simon method does not preserve the nominal power and type I error, and suggested alternative approaches. For HC studies with survival outcomes, we reveal through simulation that the conditional power and type I error over all the random realizations of the HC data have highly skewed distributions. Therefore, the sampling variability of the HC data needs to be appropriately accounted for in determining sample size. A flexible sample size formula that controls arbitrary percentiles, instead of means, of the conditional power and type I error, is derived. Although an explicit sample size formula with survival outcomes is not available, the computation is straightforward. Simulations demonstrate that the proposed method preserves the operational characteristics in a more realistic scenario where the true hazard rate of the HC group is unknown. A real data application of an advanced non-small cell lung cancer (NSCLC) clinical trial is presented to illustrate sample size considerations for HC studies in comparison of survival outcomes.

Entities:  

Keywords:  Clinical trial; historical control; percentiles of type I error and power; sample size; survival outcome

Mesh:

Year:  2015        PMID: 26098200      PMCID: PMC4688256          DOI: 10.1080/10543406.2015.1052495

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  18 in total

1.  Uniform power method for sample size calculation in historical control studies with binary response.

Authors:  J J Lee; C Tseng
Journal:  Control Clin Trials       Date:  2001-08

2.  The use of historical controls and concurrent controls to assess the effects of sulphonamides, 1936-1945.

Authors:  Irvine Loudon
Journal:  J R Soc Med       Date:  2008-03       Impact factor: 5.344

Review 3.  The combination of randomized and historical controls in clinical trials.

Authors:  S J Pocock
Journal:  J Chronic Dis       Date:  1976-03

4.  Randomized clinical trials. Perspectives on some recent ideas.

Authors:  D P Byar; R M Simon; W T Friedewald; J J Schlesselman; D L DeMets; J H Ellenberg; M H Gail; J H Ware
Journal:  N Engl J Med       Date:  1976-07-08       Impact factor: 91.245

5.  Required duration and power determinations for historically controlled studies of survival times.

Authors:  L J Emrich
Journal:  Stat Med       Date:  1989-02       Impact factor: 2.373

6.  Randomized or historical control groups in cancer clinical trials: are historical controls valid?

Authors:  E A Gehan
Journal:  J Clin Oncol       Date:  1986-07       Impact factor: 44.544

7.  The evaluation of therapies: historical control studies.

Authors:  E A Gehan
Journal:  Stat Med       Date:  1984 Oct-Dec       Impact factor: 2.373

8.  Sample size considerations for non-randomized comparative studies.

Authors:  R W Makuch; R M Simon
Journal:  J Chronic Dis       Date:  1980

9.  Mesothelioma and lung cancer mortality: a historical cohort study among asbestosis workers in Hong Kong.

Authors:  Minghui Chen; Lap Ah Tse; Ronald K F Au; Ignatius T S Yu; Xiao-rong Wang; Xiang-qian Lao; Joseph Siu-kei Au
Journal:  Lung Cancer       Date:  2011-11-30       Impact factor: 5.705

10.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

View more
  3 in total

Review 1.  Good-quality research in rare diseases: trials and tribulations.

Authors:  Davide Bolignano; Anna Pisano
Journal:  Pediatr Nephrol       Date:  2016-01-27       Impact factor: 3.714

Review 2.  Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

Authors:  Lindsay A Renfro; Lingyun Ji; Jin Piao; Arzu Onar-Thomas; John A Kairalla; Todd A Alonzo
Journal:  JCO Precis Oncol       Date:  2019-10-24

3.  Group sequential design for historical control trials using error spending functions.

Authors:  Jianrong Wu; Yimei Li
Journal:  J Biopharm Stat       Date:  2019-11-12       Impact factor: 1.051

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.